ARYx Therapeutics, Inc.
| OTC Markets: ARYX
ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets, unresolved by currently available therapies due to limitations in drug design and metabolism problems. It uses RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. Its products include: Naronapride, a proprietary serotonin type 4 (5HT4) agonist in Phase 2 development for the treatment of multiple gastrointestinal disorders; Budiodarone is a proprietary compound in Phase 2 development for the treatment of atrial fibrillation; Tecarfarin, a novel compound for oral anti-coagulation therapy; and ATI-9242, a atypical antipsychotic for the treatment of schizophrenia and other psychiatric disorders. The company was founded on February 28, 1997 by Peter G. Milner and Pascal Druzgala and is headquartered in Fremont, CA.